326 related articles for article (PubMed ID: 35902887)
1. Efficacy and safety of brolucizumab versus aflibercept in patients with neovascular age-related macular degeneration: a randomized trial in Indian patients.
Mishra SK; Kumar P; Khullar S; Joshi A; Sati A; Kumar SV; Unni D; Kumar A
Int J Retina Vitreous; 2022 Jul; 8(1):51. PubMed ID: 35902887
[TBL] [Abstract][Full Text] [Related]
2. Efficacy Outcomes of Brolucizumab Versus Aflibercept in Neovascular Age-Related Macular Degeneration Patients with Early Residual Fluid.
Singh RP; Jhaveri C; Wykoff CC; Gale RP; Staurenghi G; Iida T; Koh A; B G; Gedif K; Singer M
Ophthalmol Retina; 2022 May; 6(5):377-386. PubMed ID: 34968756
[TBL] [Abstract][Full Text] [Related]
3. Brolucizumab: Evolution through Preclinical and Clinical Studies and the Implications for the Management of Neovascular Age-Related Macular Degeneration.
Nguyen QD; Das A; Do DV; Dugel PU; Gomes A; Holz FG; Koh A; Pan CK; Sepah YJ; Patel N; MacLeod H; Maurer P
Ophthalmology; 2020 Jul; 127(7):963-976. PubMed ID: 32107066
[TBL] [Abstract][Full Text] [Related]
4. Fluid Control in Neovascular Age-Related Macular Degeneration with Brolucizumab: An Analysis of the HAWK and HARRIER Phase 3 Trials.
Regillo C; Singh R; Hamilton R; Gedif K; Best C; Koh A; Holz FG
Ophthalmologica; 2022; 245(5):403-412. PubMed ID: 35468601
[TBL] [Abstract][Full Text] [Related]
5. Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial.
Dugel PU; Jaffe GJ; Sallstig P; Warburton J; Weichselberger A; Wieland M; Singerman L
Ophthalmology; 2017 Sep; 124(9):1296-1304. PubMed ID: 28551167
[TBL] [Abstract][Full Text] [Related]
6. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
Dugel PU; Koh A; Ogura Y; Jaffe GJ; Schmidt-Erfurth U; Brown DM; Gomes AV; Warburton J; Weichselberger A; Holz FG;
Ophthalmology; 2020 Jan; 127(1):72-84. PubMed ID: 30986442
[TBL] [Abstract][Full Text] [Related]
7. HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
Dugel PU; Singh RP; Koh A; Ogura Y; Weissgerber G; Gedif K; Jaffe GJ; Tadayoni R; Schmidt-Erfurth U; Holz FG
Ophthalmology; 2021 Jan; 128(1):89-99. PubMed ID: 32574761
[TBL] [Abstract][Full Text] [Related]
8. MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid.
Khanani AM; Brown DM; Jaffe GJ; Wykoff CC; Adiguzel E; Wong R; Meng X; Heier JS;
Ophthalmology; 2022 Sep; 129(9):974-985. PubMed ID: 35537533
[TBL] [Abstract][Full Text] [Related]
9. Short-term Efficacy and Safety of Intravitreal Brolucizumab Injection for Treatment-Naive Exudate Age-related Macular Degeneration: A Multicenter Study.
Kim J; Lee SJ; Park TK; Sun HJ; Kim HD; Cho IH; Han JW; Choi KS
Korean J Ophthalmol; 2023 Oct; 37(5):365-372. PubMed ID: 37562440
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of brolucizumab in age-related macular degeneration: A systematic review of real-world studies.
Baumal CR; Sørensen TL; Karcher H; Freitas RL; Becher A; Balez S; Clemens A; Singer M; Kodjikian L
Acta Ophthalmol; 2023 Mar; 101(2):123-139. PubMed ID: 36117281
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies.
Lally DR; Loewenstein A; Arnold JJ; Yang YC; Gedif K; Best C; Patel H; Tadayoni R; Heier JS
Eye (Lond); 2023 Apr; 37(6):1242-1248. PubMed ID: 35597816
[TBL] [Abstract][Full Text] [Related]
12. Comparative assessment of subretinal hyper-reflective material in patients treated with brolucizumab versus aflibercept in HAWK and HARRIER.
Sadda S; Sarraf D; Khanani AM; Tadayoni R; Chang AA; Saffar I; Gedif K; Wong DT
Br J Ophthalmol; 2024 May; 108(6):852-858. PubMed ID: 37669850
[TBL] [Abstract][Full Text] [Related]
13. Brolucizumab in Neovascular Age-Related Macular Degeneration - Indian Real-World Experience: The BRAILLE Study.
Chakraborty D; Maiti A; Sheth JU; Boral S; Mondal S; Nandi K; Sinha T; Das A
Clin Ophthalmol; 2021; 15():3787-3795. PubMed ID: 34522081
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK.
Ogura Y; Jaffe GJ; Cheung CMG; Kokame GT; Iida T; Takahashi K; Lee WK; Chang AA; Monés J; D'Souza D; Weissgerber G; Gedif K; Koh A
Br J Ophthalmol; 2022 Jul; 106(7):994-999. PubMed ID: 34301613
[TBL] [Abstract][Full Text] [Related]
15. Real-Life Experience and Predictors of Visual Outcomes with Intravitreal Brolucizumab Switch for Treatment of Neovascular Age-Related Macular Degeneration.
Cavalleri M; Tombolini B; Sacconi R; Gatta G; Valeri R; Bandello F; Querques G
Ophthalmologica; 2023; 246(2):158-168. PubMed ID: 37040734
[TBL] [Abstract][Full Text] [Related]
16. The Effect of a Loading Dose Regimen in the Switch to Brolucizumab for Patients with Aflibercept-Resistant nAMD.
Kamao H; Mitsui E; Date Y; Goto K; Mizukawa K; Miki A
J Ophthalmol; 2024; 2024():3673930. PubMed ID: 38322501
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Brolucizumab for Diabetic Macular Edema: The KINGFISHER Randomized Clinical Trial.
Singh RP; Barakat MR; Ip MS; Wykoff CC; Eichenbaum DA; Joshi S; Warrow D; Sheth VS; Stefanickova J; Kim YS; He F; Cho GE; Wang Y; Emanuelli A
JAMA Ophthalmol; 2023 Dec; 141(12):1152-1160. PubMed ID: 37971723
[TBL] [Abstract][Full Text] [Related]
18. A randomized, open-label, multicenter study of switching to brolucizumab with or without a loading dose for patients with suboptimal anatomically controlled neovascular age-related macular degeneration-the FALCON study.
Holz FG; Schmitz-Valckenberg S; Wolf A; Agostini H; Lorenz K; Pielen A; Feltgen N; Guthoff R; Quiering C; Clemens A; Jaeger K
Graefes Arch Clin Exp Ophthalmol; 2022 Aug; 260(8):2695-2702. PubMed ID: 35188581
[TBL] [Abstract][Full Text] [Related]
19. Visual and anatomic outcomes of aflibercept treatment in treatment-naive patients with neovascular age-related macular degeneration; real-life data over 24 months.
Makri OE; Tsapardoni FN; Tsekouras IK; Lagogiannis AP; Chairas N; Pallikari A; Pagoulatos DD; Georgakopoulos CD
Hell J Nucl Med; 2019; 22 Suppl 2():55-62. PubMed ID: 31802046
[TBL] [Abstract][Full Text] [Related]
20. Switching from a Fixed Monthly Aflibercept Regimen to Bi-Monthly Brolucizumab in Refractory Cases of Neovascular Age-Related Macular Degeneration.
Kim M; Kang JE; Park YG
J Clin Med; 2024 Jun; 13(12):. PubMed ID: 38929964
[No Abstract] [Full Text] [Related]
[Next] [New Search]
